The uptick could be short-lived given the Trump administration’s raising of tariff barriers on imports from Europe.

This photo taken on March 31, 2025 shows the exhibition booth of "Invest in China" at Hannover Messe 2025 in Hannover, ...

Germany is getting €1 trillion ($1.1 trillion) in additional funding virtually for free after bond markets reacted positively to its “historic” spending bill, Deutsche Bank AG Chairman ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

HHS said the changes will save approximately $1.8bn annually. Image credit: Getty Images/ Grandbrothers The US Department of Health and Human Services (HHS) will cut 10,000 full-time employees and ...

President Trump has announced that the US will impose tariffs on all cars and trucks imported into the country. Here’s where all EVs available in the US are assembled. Shortly after taking ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...

US pharma giant Merck & Co (NYSE: MRK) today announced that the European Commission (EC) has approved Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for a new indication, marking the fourth nod ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

Mer­ck has struck a li­cens­ing deal for a car­dio­vas­cu­lar drug with Jiang­su Hen­grui Phar­ma­ceu­ti­cals, the lat­est in a flood of Chi­na deals be­ing made by … ...